ArticleJournal of clinical virology : the official publication of the Pan American Society for Clinical Virology2010
Evaluation of the Xpert Flu A Panel nucleic acid amplification-based point-of-care test for influenza A virus detection and pandemic H1 subtyping.
Article in Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 31 citations in OpenAlex.
- Point of care testing for infectious disease: ownership and quality.The Journal of antimicrobial chemotherapy · 2021Article
- Point-of-care testing for respiratory viruses in adults: The current landscape and future potential.The Journal of infection · 2015Review
- Nucleic-acid testing, new platforms and nanotechnology for point-of-decision diagnosis of animal pathogens.Methods in molecular biology (Clifton, N.J.) · 2015Article
- Evaluation of the Xpert Flu rapid PCR assay in high-risk emergency department patients.Journal of clinical microbiology · 2014Article
- Molecular detection of respiratory viruses.Clinics in laboratory medicine · 2013Review
- Evaluation of the specificity and sensitivity of a potential rapid influenza screening system.Diagnostic microbiology and infectious disease · 2013Article
- Emerging point of care tests for influenza: innovation or status quo.Influenza and other respiratory viruses · 2012Article
- Rapid, simple influenza RNA extraction from nasopharyngeal samples.Journal of virological methods · 2012Article
- Evaluation of the Cepheid Xpert Flu Assay for rapid identification and differentiation of influenza A, influenza A 2009 H1N1, and influenza B viruses.Journal of clinical microbiology · 2012Article
- Two years after pandemic influenza A/2009/H1N1: what have we learned?Clinical microbiology reviews · 2012Review
- Point-of-care testing (POCT): Current techniques and future perspectives.Trends in analytical chemistry : TRAC · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInfluenza antigenic point-of-care (POC) tests are too insensitive for individual reliable diagnosis of influenza virus infections without additional laboratory confirmation. Molecular POC tests could be a valuable alternative.
objectivesTo evaluate the first influenza molecular POC test commercially available, the Cepheid Xpert Flu A Panel designed to simultaneously detect influenza A virus and subtype A(H1N1) 2009 pandemic virus, and compare it with in-house real-time RT-PCR (qRT-PCR). STUDY
designClinical specimens positive for influenza virus and influenza virus isolates with different viral loads and of different type and subtype were used to determine the analytical reactivity and sensitivity. A panel of pathogen negative specimens and isolates of 19 different respiratory pathogens were used to determine the analytical specificity.
resultsExcept A(H9N2) virus the Xpert Flu A Panel detected A(H1N1) seasonal and 2009 pandemic, A(H3N2), A(H5N2), A(H5N1) and A(H7N7) viruses and correctly subtyped A(H1N1) 2009 virus. Analytical sensitivity was similar to qRT-PCR in the range of 400-5000 viral particles per ml. However, of most subtypes some specimens with cycle threshold values greater than 30 in qRT-PCR and A(H1N1) 2009 specimens with inconsistent results in the qRT-PCR due to primer or probe mismatches were not detected in the Xpert Flu A Panel. Analytical specificity was 100%.
conclusionsThe Xpert Flu A Panel is the first commercially available POC molecular test for detection of influenza A virus and determination of the H1 2009 subtype and is analytically reasonable sensitive compared with qRT-PCR and highly specific and therefore a welcome alternative to antigenic POC tests.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.